Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 4/2009

Content (22 Articles)

Review

Thalidomide-induced severe hepatotoxicity

Vrushali Dabak, Philip Kuriakose

Original Article

Targeting MET transcription as a therapeutic strategy in multiple myeloma

Cornel J. Phillip, Christine M. Stellrecht, Ramadevi Nimmanapalli, Varsha Gandhi

Original Article

Renal dysfunction during and after high-dose methotrexate

Myke R. Green, Marc C. Chamberlain

Original Article

Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice

Jianxia Guo, Robert A. Parise, Erin Joseph, Merrill J. Egorin, John S. Lazo, Edward V. Prochownik, Julie L. Eiseman

Original Article

Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes?

Byeong-Bae Park, Ji Eun Uhm, Eun Yoon Cho, Yoon La Choi, Sang Hoon Ji, Do Hyun Nam, Jung Il Lee, Won Park, Seung Jae Huh, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im

Original Article

Targeted constitutive activation of signal transducer and activator of transcription 3 in human hepatocellular carcinoma cells by cucurbitacin B

Meixia Zhang, Hongliang Zhang, Chunyan Sun, Xiaolei Shan, Xiaolin Yang, Jesse Li-Ling, Yihui Deng

Original Article

Inhibition of activation of dsRNA-dependent protein kinase and tumour growth inhibition

Helen L. Eley, Pria S. McDonald, Steven T. Russell, Michael J. Tisdale

Original Article

Inhibition of NF-κB-mediated transcription and induction of apoptosis in human breast cancer cells by epoxypseudoisoeugenol-2-methyl butyrate

Guoyi Ma, Nurhayat Tabanca, K. Husnu Can Baser, Nese Kirimer, David S. Pasco, Ikhlas A. Khan, Shabana I. Khan

Original Article

CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells

Zhenfeng Duan, Rachel Y. Ames, Meagan Ryan, Francis J. Hornicek, Henry Mankin, Michael V. Seiden

Original Article

Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil

Sofia B. Gustafsson, Theres Lindgren, Maria Jonsson, Stig O. P. Jacobsson

Original Article

Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer

Dawn P. G. Brown, Helen Chin-Sinex, Bei Nie, Marc S. Mendonca, Mu Wang

Clinical Trial Report

Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy

Markos Leggas, Kuei-Ling Kuo, Francisco Robert, Gretchen Cloud, Mollie deShazo, Ruiwen Zhang, Mao Li, Hui Wang, Steve Davidson, John Rinehart

Short Communication

Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report

Celalettin Camci, Alper Sevinc, Yilmaz Aslan, Mehmet Emin Kalender, Suleyman Buyukberber

Short Communication

Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma

S. V. Picton, J. Keeble, V. Holden, J. Errington, A. V. Boddy, G. J. Veal

Short Communication

BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line

Manny D. Bacolod, Randy Fehdrau, Stewart P. Johnson, Nancy S. Bullock, Darell D. Bigner, Michael Colvin, Henry S. Friedman

Letter to the Editor

Successful treatment with a rituximab-based regimen of a splenic marginal zone lymphoma with villous lymphocytes in a very frail patient on maintenance dialysis

Pasquale Niscola, Roberto Palumbo, Laura Scaramucci, Andrea Tendas, Luca Cupelli, Marco Giovannini, Daniela Piccioni, Teresa Dentamaro, Alessio Pio Perrotti, Paolo de Fabritiis

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine